Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Policy & Acquisitions

Mergers & Acquisitions

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Mergers & Acquisitions

214 stories · every one Fact-Checked
charlesdeluvio-Lks7vei-eAg-unsplashMergers & AcquisitionsAbbVie Builds Pain Portfolio Through Broad Licensing Pact With HaiscoAbbVie and Haisco Pharmaceutical have entered an exclusive global licensing agreement to develop and commercialize multiple investigational pain therapies outside Greater China, with Haisco eligible for up to…14 Apr 2026 · 2 min read
Fact-Checked
steve-a-johnson-1FD-E7Ioblw-unsplashMergers & AcquisitionsNovo Nordisk Taps OpenAI to Supercharge the Drug Discovery EngineNovo Nordisk has partnered with OpenAI to apply advanced AI across research, manufacturing, and commercial operations, aiming to accelerate drug discovery, improve efficiency, and expand AI-driven capabilities company-wide…14 Apr 2026 · 2 min read
Fact-Checked
vitaly-gariev-n0WOanjDMeA-unsplashMergers & AcquisitionsRegeneron and Telix Set 50/50 Course for Targeted Radiopharma ExpansionRegeneron and Telix announced a global collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies targeting solid tumors.14 Apr 2026 · 2 min read
Fact-Checked
Boehringer Ingelheim's JASCAYD (nerandomilast), the first oral PDE4B inhibitor, receives European Commission approval for treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).Mergers & AcquisitionsBoehringer, Click Move CT-155 to Frontline in SchizophreniaClick Therapeutics will lead commercialization of CT-155 after Boehringer Ingelheim transfers full product responsibility and invests $50 million, supported by Phase III CONVOKE data showing improvement in schizophrenia…12 Apr 2026 · 3 min read
Fact-Checked
2045Mergers & AcquisitionsFrom Images to Insights: Imagene AI Partners Daiichi SankyoImagene AI and Daiichi Sankyo entered a collaboration to use multimodal AI and pathology data to support biomarker discovery, patient stratification, and response prediction in oncology development.11 Apr 2026 · 2 min read
Fact-Checked
Gemini_Generated_Image_jl66mrjl66mrjl66Mergers & AcquisitionsRoche, C4 Therapeutics Launch “Two-in-One” Targeted Cancer StrategyC4 Therapeutics and Roche expand their long-standing partnership to advance degrader-antibody conjugates, combining targeted protein degradation with ADC technology across multiple oncology programs.11 Apr 2026 · 3 min read
Fact-Checked
102581Mergers & AcquisitionsCosette Pharmaceuticals Acquires SYMPAZAN Portfolio from Assertio HoldingsCosette Pharmaceuticals is expanding its branded portfolio through the acquisition of U.S. commercial rights to SYMPAZAN and several established pain and inflammation therapies from Assertio.9 Apr 2026 · 2 min read
Fact-Checked
48118Clinical TrialsBoehringer–BioNTech Partner on ES-SCLC Immunotherapy TrialBoehringer Ingelheim and BioNTech have entered a clinical collaboration to evaluate obrixtamig in combination with pumitamig in extensive-stage small cell lung cancer.9 Apr 2026 · 2 min read
Fact-Checked
AstellasMergers & AcquisitionsAstellas Taps Dyno’s AI-Designed AAV Capsid to Tackle Muscle Gene Therapy Dosing ChallengeAstellas Pharma has exercised its option to license an AI-engineered AAV capsid from Dyno Therapeutics for skeletal muscle gene therapy.9 Apr 2026 · 2 min read
Fact-Checked
Gemini_Generated_Image_ye1doqye1doqye1dMergers & AcquisitionsShionogi Secures Up to $482 Million BARDA Project BioShield Contract for FetrojaImage Courtesy: Shionogi Shionogi secures a BARDA Project BioShield contract worth up to $482 million to support U.S. manufacturing, procurement…8 Apr 2026 · 2 min read
Fact-Checked
Leiden_Ext_Entrance_Vertex_2021_11zonMergers & AcquisitionsHalozyme and Vertex Sign Global Licensing Deal for Hypercon Drug Delivery TechnologyHalozyme’s subsidiary signed an exclusive global agreement with Vertex to apply Hypercon™ drug delivery technology to up to three targets, with upfront payment, milestones, and royalties tied to…8 Apr 2026 · 2 min read
Fact-Checked
167284Mergers & AcquisitionsBiogen Licenses Alloy AntiClastic ASO TechnologyAlloy Therapeutics has entered a collaboration and license agreement with Biogen to apply its AntiClastic ASO platform for developing antisense therapeutics against multiple undisclosed targets.8 Apr 2026 · 3 min read
Fact-Checked
Page 16 of 18